Alumis Inc. (NASDAQ:ALMS) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in Alumis Inc. (NASDAQ:ALMS) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 315,571 shares of the company’s stock after acquiring an additional 9,891 shares during the quarter. Geode Capital Management LLC owned 0.67% of Alumis worth $2,481,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. State Street Corp acquired a new position in shares of Alumis in the 3rd quarter worth approximately $866,000. Barclays PLC acquired a new position in shares of Alumis in the 3rd quarter worth approximately $197,000. Charles Schwab Investment Management Inc. grew its position in shares of Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock worth $891,000 after acquiring an additional 4,808 shares in the last quarter. Norges Bank acquired a new position in shares of Alumis in the 4th quarter worth approximately $1,606,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Alumis in the 3rd quarter worth approximately $191,000.

Alumis Trading Down 3.7 %

Shares of ALMS opened at $4.12 on Tuesday. Alumis Inc. has a one year low of $3.18 and a one year high of $13.53. The company has a 50-day moving average of $5.48 and a two-hundred day moving average of $7.60.

Analysts Set New Price Targets

ALMS has been the topic of several recent research reports. Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. HC Wainwright cut their price target on Alumis from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, April 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.86.

Insiders Place Their Bets

In other Alumis news, Director Alan Colowick bought 16,104 shares of Alumis stock in a transaction on Tuesday, April 1st. The stock was purchased at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the purchase, the director now directly owns 16,104 shares of the company’s stock, valued at $112,244.88. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martin Babler bought 15,650 shares of Alumis stock in a transaction on Tuesday, April 1st. The stock was acquired at an average price of $6.44 per share, with a total value of $100,786.00. Following the completion of the purchase, the chief executive officer now directly owns 106,454 shares of the company’s stock, valued at approximately $685,563.76. The trade was a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.